Premium
Desensitization for prevention of chronic antibody‐mediated rejection after kidney transplantation
Author(s) -
Tanabe Kazunari,
Inui Masashi
Publication year - 2013
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.12260
Subject(s) - medicine , plasmapheresis , desensitization (medicine) , rituximab , kidney transplantation , immunology , transplantation , antibody , panel reactive antibody , receptor
Abstract Chronic antibody‐mediated rejection (C‐ AMR ) is the most important and leading cause of graft loss after kidney transplantation. Although it is well known that chronic renal allograft dysfunction or failure is caused by various immunological or non‐immunological factors, donor‐specific anti‐human leukocyte antigen antibodies ( DSA s) are considered to be the most detrimental to graft survival and could cause C‐ AMR . Despite the use of intensive treatment for C‐ AMR , outcomes have not always been promising. Recently, prevention, rather than treatment, of C‐ AMR has been attempted, and this approach appears to be a more effective option for reducing the incidence of C‐ AMR and, ultimately, improving long‐term survival. To prevent C‐ AMR , removal of antibodies, inactivation of antibodies, and prevention of antibody production after kidney transplantation are essential. Preconditioning treatment including plasmapheresis, intravenous immunoglobulin, and rituximab injection seems the most effective of current desensitization protocols. In this minireview, we will focus on the prevention of C‐ AMR through desensitization and improving long‐term graft survival.